Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 26, 2012

Boosting Clinical Trial Participation

  • Clinical Research Advantage (CRA) entered into a strategic agreement with Quintiles to increase clinical trial participation. The firms aim to emphasize safety, as well as improve study efficiencies and data quality in medical research. CRA offers a mechanism for medical professionals to conduct Phase II–IV clinical research trials by providing coordinating and regulatory support.

    “Clinical Research Advantage impressed us with their high standards for quality, high patient enrollments, and exceptional study start-up abilities,” says Lindy Jones, svp, integrated site services, Quintiles. “Many chronic conditions such as diabetes and heart disease are now managed in the community. It is imperative that these patient populations have the opportunity to participate in studies and be a part of the quest to develop new and better medicines for conditions that have a significant impact on both individuals and society.”



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »